

Tetrahedron 64 (2008) 4246-4253

Tetrahedron

www.elsevier.com/locate/tet

Diversity oriented synthesis of fused-ring 1,3-oxazines from carbohydrates as biorenewable feedstocks

Lal Dhar S. Yadav*, Vishnu P. Srivastava, Vijai K. Rai, Rajesh Patel

Green Synthesis Lab, Department of Chemistry, University of Allahabad, Allahabad 211 002, India

Received 16 December 2007; received in revised form 22 February 2008; accepted 26 February 2008 Available online 29 February 2008

Abstract

Microwave enhanced diversity oriented synthesis (MEDOS) of various *N*- and *O*-heterocyclic systems fused with 1,3-oxazine ring is reported. The synthesis represents a new montmorillonite K-10 clay-catalyzed green protocol, which utilizes D-glucose/D-xylose as biorenewable feedstocks. D-Glucose/D-xylose-derived 1,3-oxazin-2-ones(thiones) either directly undergo K-10 clay-catalyzed cyclization to yield pyrano-/furo-1,3-oxazine systems under solvent-free microwave irradiation conditions or afford azolo-/azino-1,3-oxazines when subjected to Malaprade reaction followed by cyclization with appropriate reagents, viz. phenylhydrazine, hydroxylamine, acetamidine, phenylurea and semi(thiosemi)-carbazide.

© 2008 Elsevier Ltd. All rights reserved.

Keywords: Diversity oriented synthesis; 1,3-Oxazines; Solvent-free; Microwaves; Montmorillonite K-10; Carbohydrates

1. Introduction

Diversity oriented synthesis (DOS) has emerged as a valuable approach to generate libraries of various classes of compounds. Efforts in DOS have produced powerful new biological probes and also served as a new driving force for synthetic organic chemistry. Although the earlier combinatorial chemical libraries of drug-like small molecules were reported over a decade ago, DOS remains relatively less extensively studied.

Carbohydrates are the major raw materials for organic chemicals with tailor-made industrial applications. This is because they are inexpensive, accessible in ton-scale and have better worked out ensuing chemistry. Advantages of the application of microwave (MW) irradiation in conjunction with mineral supported reagents under solvent-free conditions have now been well established.

The 1,3-oxazine nucleus features prominently in many biologically important natural products⁷ and other bioactive molecules.^{8–10} The most outstanding of these is Sustiva

(Efavirenz), a non-nucleoside reverse transcriptase inhibitor that has been approved by the FDA in 1998 and is presently in clinical use for the treatment of AIDS. This has been the prime driving force for the synthesis of various compounds incorporating the 1,3-oxazine moiety. 1,3-Oxazin-2-one derivatives have been used as the key intermediates in the synthesis of several natural products, and have also been recognized as chiral auxiliaries in asymmetric synthesis. 11

Along with the synthetic strategies reported in the literature for oxazines, $^{12-19}$ we have also reported the synthesis of 1,3-oxazin-2-ones(thiones) fused with benzene $\operatorname{ring}^{20-23}$ and their C- and N-nucleoside analogues using salicylaldehyde as a bifunctional building block. $^{24-26}$ To the best of our knowledge, there has been no report on the synthesis of 1,3-oxazin-2-one-(thione) fused with various pharmaceutically and agrochemically important N- and O-heterocycles, starting from D-glucose and D-xylose, although they appear to be attractive scaffolds to be utilized for exploiting chemical diversity and generating a drug-like library to screen for potential new leads.

Considering the above valid points and our ongoing efforts to develop new cyclization processes, ²⁰⁻²⁸ we describe herein the microwave enhanced diversity oriented synthetic (MEDOS) approach for the unprecedented synthesis of pharmaceutically

^{*} Corresponding author. Tel.: +91 5322500652; fax: +91 5322460533. E-mail address: ldsyaday@hotmail.com (L.D.S. Yaday).

and agrochemically important furo-, isoxazolo-, oxazino-, pyrazolo-, pyrano-, pyrimidino-, pyrazinoxazin-2-ones(thiones) and oxazinoxazin-2,6-ones(thiones) using D-glucose and D-xylose under solvent-free mineral supported reaction conditions (Scheme 1).

CHO (CHOH)_n CH₂OH (CHOH)_n CH₂OH (CHOH)_n = 3, D-xylose
$$n = 4$$
, D-glucose $n = 4$, D-glucose $n =$

Scheme 1. MEDOS of fused-ring 1,3-oxazin-2-ones(thiones) from p-glucose and p-xylose.

2. Results and discussion

The hitherto unreported 1,3-oxazin-2-ones(thiones) **3** were obtained via montmorillonite K-10 clay-catalyzed domino cycloisomerization, dehydrazination and dehydration of D-glucose/D-xylose semi(thiosemi)carbazones **4** under solvent-free MW irradiation conditions in a one-pot procedure (Scheme 2). The mechanism shown in Scheme 2 is supported by the formation of hydrazine during the reaction. It was noted that other mineral catalysts, viz. silica gel, neutral or basic alumina, were far less effective resulting in either no reaction (in the case of basic alumina) or relatively very low yields (15–28%) of **3** (in the cases of silica gel and neutral alumina).

1,3-Oxazin-2-ones(thiones) **3** were synthesized in 79–85% yields by solvent-free MW irradiation of p-glucose/p-xylose **1**, semi(thiosemi)carbazide **2** and montmorillonite K-10 clay (Scheme 2). 1,3-Oxazin-2-ones(thiones) **3** were subjected to Malaprade reaction (Scheme 3) to afford aldehydes **5** and **6**, which were converted into the target compounds **7–11**; compounds **14** and **16** by judicious use of catalysts and reagents (Schemes 4, 5, 7 and 8). The MEDOS strategy for the envisaged solvent-free synthesis of 1,3-oxazin-2-one(thione)-fused isoxazoles **7**, pyrazoles **8** and pyrimidines **9** consisted in microwave (MW) irradiation of an intimate solvent-free mixture of compound **5**, montmorillonite K-10 clay and sodium acetate with hydroxylamine hydrochloride, phenylhydrazine hydrochloride and acetamidine hydrochloride, respectively, at 80 °C for 5–12 min (Scheme 4). Isolation and purification

$$\begin{array}{c} \text{CHO} \\ \text{CHOH})_n \\ \text{CH}_2\text{OH} \\ n = 3, \text{ D-xylose} \\ n = 4, \text{ D-glucose} \\ \end{array} \\ \begin{array}{c} \text{MW}, \text{ K-10 clay} \\ \text{MW}, \text{ K-10 clay} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{OH} \\ \text{NH} \\ \text{CHOH})_{n-2} \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NNH}_2 \\ \text{CHOH})_{n-2} \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NNH}_2 \\ \text{CHOH})_{n-2} \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NNH}_2 \\ \text{CHOH})_{n-2} \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{CHOH})_{n-2} \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{CH}_2\text{OH} \\ \end{array} \\ \begin{array}{c} \text{NH}_2 \\ \text{NH}_$$

Scheme 2. Plausible mechanism for the formation of 1,3-oxazin-2-ones-(thiones) 3 from p-glucose/p-xylose semi(thiosemi)carbazones 4.

by recrystallization from ethanol afforded **7–9** in 80–93% yields. Similarly, compounds **10** and **11** were synthesized in 81–92% yields by MW irradiation of an intimate solvent-free mixture of compound **6**, montmorillonite K-10 clay and sodium acetate with hydroxylamine hydrochloride and phenylhydrazine hydrochloride, respectively, at 90 °C for 5–11 min (Scheme 5).

Scheme 3. Malaprade reaction to afford aldehydes 5 and 6.

The formation of compounds 7–11 may be tentatively explained by acid-catalyzed condensation of hydroxylamine, phenylhydrazine or acetamidine with aldehydic >C=O group of 5 and 6 followed by cyclodehydration of the resulting condensation product (Schemes 4 and 5). Montmorillonite K-10 clay-catalyzed cyclodehydration of 1,3-oxazin-2-ones(thiones) 3 (Scheme 6) under solvent-free MW irradiation afforded furo-1,3-oxazin-2-ones(thiones) 12 (83–85% yields) and pyrano-1,3-oxazin-2-ones(thiones) 13 in 87–90% yields (Table 1). The use of other mineral catalysts, viz. silica gel, neutral or basic alumina, resulted in relatively very low yields of 7–9 (19–35%) and 21–29% of 12 and 13.

The MEDOS strategy for compounds **14** was successful when an intimate mixture of phenylurea, ammonium acetate,

$$\begin{array}{c} \begin{array}{c} \text{Ph} & \text{H} & \text{OH} \\ \text{N:} & \text{N} \\ \text{AcONa} \\ \text{K-10} \\ \text{MW} \end{array} \begin{array}{c} \text{NH}_2\text{OH} \\ \text{Sa, } \text{X = O} \\ \text{Sb, } \text{X = S} \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_3 \\ \text{NH}_4 \\ \text{NH}_4 \\ \text{NI} & \text{N} \\ \text{NH}_5 \\ \text{NH}_5 \\ \text{NH}_6 \\ \text{NI} & \text{N} \\ \text{NI} & \text{NI} \\ \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{NI} & \text{NI} \\ \text{NI} & \text{NI} & \text{$$

Scheme 4. Routes for the formation of compounds 7-9 from compounds 5.

$$\begin{array}{c|c} \mathbf{6} & \underbrace{\begin{array}{c} NH_2OH \\ AcONa \\ K-10 \\ MW \end{array}} & \underbrace{\begin{array}{c} H \\ O: \Psi \\$$

Scheme 5. Formation of compounds 10 and 11 from 6.

HOW NOW K-10

ON
$$K-10$$

ON $K-10$

HOW $K-10$

ON $K-10$

HOW $K-10$

ON $K-10$

HOW $K-10$

ON $K-10$

ON

Scheme 6. Formation of compounds 12 and 13 from 3.

K-10 clay and **5** was subjected to MW irradiation for 9–10 min at 90 °C (Scheme 7). Isolation and purification by recrystallization from ethanol afforded 4-amino oxazine-2,6-diones(6-one-2-thiones) **14** in 89–93% yields (Table 1). That the first step in the present three component coupling strategy involves the conversion of phenylurea into phenyl isocyanate intermediate was supported by its trapping as *p*-tolylurea derivatives. Phenylurea with ammonium acetate and **5** yielded an aldimine intermediate **14**′, which upon cycloisomerization afforded compounds **14** (Scheme 7). Furthermore, MW irradiation of thoroughly mixed semicarbazones **15** and Montmorillonite K-10 clay at 90 °C for 8–11 min afforded compounds **16** in 90–91% yields (Table 1) via domino cycloisomerization and dehydrazination reactions of **15** (Scheme 8).

Table 1 Microwave enhanced synthesis of compounds $\bf 3, 4$ and $\bf 7-\bf 16$ under solvent-free conditions

Compound	Time ^a (min)	Yield ^{b,c} (%)	Compound	Time ^a (min)	Yield ^{b,c} (%)
3a	3	83	10b	7	88
3b	2	79	11a	9	92
3c	2	81	11b	11	91
3d	4	85	12a	8	85
7a	5	80	12b	8	83
7b	5	83	13a	7	90
8a	12	91	13b	8	87
8b	11	93	14a	10	89
9a	7	85	14b	9	93
9b	9	82	16a	11	91
10a	5	81	16b	8	90

- ^a Microwave irradiation time.
- ^b Yield of isolated and purified products.
- c All compounds gave C, H and N analyses within $\pm 0.36\%$, and satisfactory spectral (IR, 1 H NMR, 13 C NMR and EIMS) data.

Scheme 7. Plausible mechanism for the formation of compounds 14 from phenylurea.

The mechanism shown in Scheme 8 is supported by the formation of hydrazine during the reaction. The relatively poor yields (11–19%) of **16** were obtained by using other mineral catalysts, viz. silica gel, neutral or basic alumina.

HO, N
$$H_2$$
CONHNH₂·HCl H_2 N H_2

Scheme 8. Plausible mechanism for the formation of 15 from 16.

3. Conclusion

In summary, we have developed a general, straightforward diversity oriented synthetic approach for the synthesis of various 1,3-oxazin-2-one(thione)-fused *N*- and *O*-heterocyclic systems using D-glucose and D-xylose as biorenewable resources under solvent-free microwave irradiation conditions. The present protocol is an excellent illustration for the utilization of carbohydrate feedstocks in organic synthesis.

4. Experimental

4.1. General

Melting points were determined by open glass capillary method and are uncorrected. IR spectra in KBr were recorded on a Perkin–Elmer 993 IR spectrophotometer. 1 H NMR spectra were recorded on a Bruker WM-40 C (400 MHz) FT spectrometer in DMSO- d_6 using TMS as an internal reference. 13 C NMR spectra were recorded on the same instrument at 100 MHz in DMSO- d_6 and TMS was used as internal reference. Mass (EI) spectra were recorded on a JEOL D-300 mass spectrometer. Elemental analyses were carried out in a Coleman automatic carbon, hydrogen and nitrogen analyzer. A Chemical Laboratory Microwave Oven (Model: BP-310/50, 230 volt, 50 Hz power input) was used for all the experiments. All chemicals used were of reagent grade and were used as-received without further purification. Silica gel-G was used for TLC.

4.2. 1,3-Oxazin-2-ones(thiones) 3: general procedure

Thoroughly mixed D-xylose/D-glucose (1 mmol) 1, semicarbazide hydrochloride/thiosemicarbazide (1 mmol) 2, sodium acetate (1 mmol) and montmorillonite K-10 clay (0.10 g) were taken in a 20 mL vial and subjected to microwave irradiation for 2—4 min at 90 °C. After completion of the reaction as indicated by TLC, water (10 mL) was added to give the crude product and recrystallized from ethanol to obtain analytically pure sample of 3.

4.2.1. Compound 3a

White solid (83%), mp 147–149 °C. IR (KBr) ν_{max} 3392–3385, 3011, 1692, 1635 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ:

3.85 (dd, 1H, $J_{4\text{H,5H}}=8.1$ Hz, $J_{5\text{H,6H}}=3.4$ Hz, 5-H), 4.11 (dd, 1H, $J_{2'\text{Ha,2'Hb}}=10.1$ Hz, $J_{1'\text{H,2'Ha}}=5.4$ Hz, 2'H_a), 4.23 (dd, 1H, $J_{6\text{H,1'H}}=6.1$ Hz, $J_{5\text{H,6H}}=3.4$ Hz, 6-H), 4.30 (ddd, 1H, $J_{6\text{H,1'H}}=6.1$ Hz, $J_{1'\text{H,2'Ha}}=5.4$ Hz, $J_{1'\text{H,2'Hb}}=2.9$ Hz, 1'H), 4.63 (dd, 1H, $J_{2'\text{Ha,2'Hb}}=10.1$ Hz, $J_{1'\text{H,2'Hb}}=2.9$ Hz, 2'H_b), 4.93–5.24 (br s, 3H, 3×OH, exchangeable with D₂O), 7.65 (d, 1H, $J_{4\text{H,5H}}=8.1$ Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 64.5, 65.3, 73.7, 86.2, 163.1, 172.5. MS (FAB) m/z 176 (MH⁺). Anal. Calcd for C₆H₉NO₅: C, 41.15; H, 5.18; N, 8.00%. Found: C, 41.43; H, 5.09; N, 7.82%.

4.2.2. Compound 3b

White solid (79%), mp 156–158 °C. IR (KBr) $\nu_{\rm max}$ 3391–3385, 3015, 1695, 1636 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.87 (dd, 1H, $J_{\rm 4H,5H}$ =8.1 Hz, $J_{\rm 5H,6H}$ =3.4 Hz, 5-H), 4.10 (dd, 1H, $J_{\rm 2'Ha,2'Hb}$ =10.2 Hz, $J_{\rm 1'H,2'Ha}$ =5.4 Hz, 2'H_a), 4.19 (dd, 1H, $J_{\rm 6H,1'H}$ =6.1 Hz, $J_{\rm 5H,6H}$ =3.4 Hz, 5-H), 4.33 (ddd, 1H, $J_{\rm 6H,1'H}$ =6.1 Hz, $J_{\rm 1'H,2'Ha}$ =5.4 Hz, $J_{\rm 1'H,2'Hb}$ =2.9 Hz, 1'H), 4.59 (dd, 1H, $J_{\rm 2'Ha,2'Hb}$ =10.2 Hz, $J_{\rm 1'H,2'Hb}$ =2.9 Hz, 2'H_b), 4.93–5.27 (br s, 3H, 3×OH, exchangeable with D₂O), 7.69 (d, 1H, $J_{\rm 4H,5H}$ =8.1 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 64.4, 65.7, 71.9, 85.7, 104.8, 163.0, 192.3. MS (FAB) m/z 192 (MH⁺). Anal. Calcd for C₆H₉NO₄S: C, 37.69; H, 4.74; N, 7.33%. Found: C, 37.95; H, 4.91; N, 7.23%.

4.2.3. Compound **3c**

White solid (81%), mp 161–164 °C. IR (KBr) ν_{max} 3398–3382, 3008, 1690, 1635 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.88 (ddd, 1H, $J_{2'\text{H},3'\text{Ha}}$ =5.4 Hz, $J_{1'\text{H},2'\text{H}}$ =4.6 Hz, $J_{2'\text{H},3'\text{Hb}}$ =2.7 Hz, 2'H), 3.91 (dd, 1H, $J_{4\text{H},5\text{H}}$ =8.1 Hz, $J_{5\text{H},6\text{H}}$ =3.1 Hz, 5-H), 4.03 (dd, 1H, $J_{3'\text{Ha},3'\text{Hb}}$ =10.5 Hz, $J_{2'\text{H},3'\text{Ha}}$ =5.4 Hz, 3'Ha), 4.27 (dd, 1H, $J_{6\text{H},1'\text{H}}$ =6.7 Hz, $J_{5\text{H},6\text{H}}$ =3.1 Hz, 6-H), 4.37 (dd, 1H, $J_{6\text{H},1'\text{H}}$ =6.7 Hz, $J_{1'\text{H},2'\text{H}}$ =4.6 Hz, 1'H), 4.59 (dd, 1H, $J_{3'\text{Ha},3'\text{Hb}}$ =10.5 Hz, $J_{2'\text{H},3'\text{Hb}}$ =2.7 Hz, 3'H_b), 5.01–5.37 (br s, 4H, 4×OH, exchangeable with D₂O), 7.63 (d, 1H, $J_{4\text{H},5\text{H}}$ =8.1 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS): δ 55.7, 64.3, 65.9, 71.7, 73.5, 81.5, 163.2, 174.8. MS (FAB) m/z 206 (MH⁺). Anal. Calcd for C₇H₁₁NO₆: C, 40.98; H, 5.40; N, 6.83%. Found: C, 40.73; H, 5.57; N, 6.71%.

4.2.4. Compound 3d

White solid (85%), mp 142–144 °C. IR (KBr) ν_{max} 3399–3384, 3012, 1693, 1638 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ:

3.81 (ddd, 1H, $J_{2'H,3'Ha}$ =5.4 Hz, $J_{1'H,2'H}$ =4.6 Hz, $J_{2'H,3'Hb}$ =2.7 Hz, 2'H), 3.90 (dd, 1H, $J_{4H,5H}$ =8.1 Hz, $J_{5H,6H}$ =3.1 Hz, 5-H), 4.04 (dd, 1H, $J_{3'Ha,3'Hb}$ =10.5 Hz, $J_{2'H,3'Ha}$ =5.4 Hz, 3'H_a), 4.23 (dd, 1H, $J_{6H,1'H}$ =6.7 Hz, $J_{5H,6H}$ =3.1 Hz, 6-H), 4.41 (dd, 1H, $J_{6H,1'H}$ =6.7 Hz, $J_{1'H,2'H}$ =4.6 Hz, 1'H), 4.57 (dd, 1H, $J_{3'Ha,3'Hb}$ =10.5 Hz, $J_{2'H,3'Hb}$ =2.7 Hz, 3'H_b), 5.03–5.33 (br s, 4H, 4×OH, exchangeable with D₂O), 7.66 (d, 1H, $J_{4H,5H}$ =8.1 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS): δ 55.6, 64.8, 65.6, 71.6, 73.8, 81.3, 163.1, 192.9. MS (FAB) m/z 222 (MH⁺). Anal. Calcd for C₇H₁₁NO₅S: C, 38.00; H, 5.01; N, 6.33%. Found: C, 38.32; H, 5.16; N, 6.29%.

4.3. Malaprade reaction to afford aldehydes **5** and **6**: general procedure

To a well stirred ice-cold solution of 1,3-oxazin-2-ones-(thiones) **3** (1 mmol) in 15 mL ethanol was added dropwise with stirring a solution of sodium periodate (2 mmol) in 8 mL of water. The reaction mixture was further stirred for 2-3 h at rt. After completion of reaction, as indicated by TLC, solvent was evaporated under reduced pressure to get solid residue, which was extracted with ethyl acetate (3×10 mL). The extract was filtered and filtrate was concentrated under vacuum to leave the crude product, which on recrystallization from ethanol afforded pure compounds **5** as white solid. The procedure followed for **6** was exactly the same, except that in this case 1 mmol of sodium periodate was used instead of 2 mmol of sodium periodate for **5**.

4.3.1. Compound **5a**

White solid (74%), mp 120–122 °C. IR (KBr) $\nu_{\rm max}$ 3391, 3009, 1715, 1695, 1632 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ: 3.98 (dd, 1H, $J_{\rm 4H,5H}$ =7.8 Hz, $J_{\rm 5H,6H}$ =3.2 Hz, 5-H), 4.95 (br s, 1H, OH, exchangeable with D₂O), 5.57 (d, 1H, $J_{\rm 5H,6H}$ =3.2 Hz, 6-H), 7.53 (d, 1H, $J_{\rm 4H,5H}$ =7.8 Hz, 4-H), 9.85 (s, 1H, CHO). ¹³C NMR (DMSO- d_6 /TMS) δ: 61.9, 92.5, 163.1, 172.5, 176.5. MS (FAB) m/z 144 (MH⁺). Anal. Calcd for C₅H₅NO₄: C, 41.97; H, 3.52; N, 9.79%. Found: C, 41.73; H, 3.47; N, 9.92%.

4.3.2. Compound 5b

White solid (79%), mp 132–134 °C. IR (KBr) $\nu_{\rm max}$ 3390, 3011, 1718, 1635, 1055 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ: 3.95 (dd, 1H, $J_{4\rm H,5H}$ =7.9 Hz, $J_{5\rm H,6H}$ =3.2 Hz, 5-H), 4.98 (br s, 1H, OH, exchangeable with D₂O), 5.53 (d, 1H, $J_{5\rm H,6H}$ = 3.2 Hz, 6-H), 7.55 (d, 1H, $J_{4\rm H,5H}$ =7.9 Hz, 4-H), 9.87 (s, 1H, CHO). ¹³C NMR (DMSO- d_6 /TMS) δ: 62.3, 92.1, 163.3, 172.1, 192.5. MS (FAB) m/z 160 (MH⁺). Anal. Calcd for C₅H₅NO₃S: C, 37.73; H, 3.17; N, 8.80%. Found: C, 37.95; H, 3.56; N, 8.89%.

4.3.3. Compound **6a**

White solid (81%), mp 112–113 °C. IR (KBr) $\nu_{\rm max}$ 3393, 3385, 3012, 1713, 1697, 1634 cm⁻¹. ¹H NMR (DMSO- d_6/J TMS) δ : 3.71 (d, 1H, $J_{1'{\rm H},6{\rm H}}$ =5.9 Hz, 1'H), 4.01 (dd, 1H, $J_{4{\rm H},5{\rm H}}$ =7.8 Hz, $J_{5{\rm H},6{\rm H}}$ =3.5 Hz, 5-H), 4.97–5.19 (br s, 2H, 2×OH, exchangeable with D₂O), 5.58 (dd, 1H,

 $J_{1'H,6H}$ =5.9 Hz, $J_{5H,6H}$ =3.5 Hz, 6-H), 7.61 (d, 1H, $J_{4H,5H}$ =7.8 Hz, 4-H), 9.91 (s, 1H, CHO). ¹³C NMR (DMSO- d_6 /TMS) δ : 62.5, 78.1, 91.8, 163.7, 172.1, 176.8. MS (FAB) m/z 174 (MH⁺). Anal. Calcd for C₆H₇NO₅: C, 41.63; H, 4.08; N, 8.09%. Found: C, 41.43; H, 4.29; N, 8.23%.

4.3.4. Compound **6b**

4.4. Isoxazolo-, pyrazolo- and pyrimidinoxazin-2-ones(thiones) 7-9: general procedure

An intimate solvent-free mixture of **5** (0.143 g for **5a**, 1 mmol), sodium acetate (0.082 g, 1 mmol) and hydroxylamine hydrochloride (0.069 g, 1 mmol) or phenylhydrazine hydrochloride (0.145 g, 1 mmol) or acetamidine hydrochloride (0.095 g, 1 mmol) in the presence of montmorillonite K-10 clay (0.10 g) was taken in a 20 mL vial and subjected to MW irradiation at 80 °C for 5-12 min to get the crude product, which was extracted with dichloromethane (3×10 mL). The extract was filtered, the filtrate was evaporated under reduced pressure and the residue thus obtained was recrystallized from ethanol to obtain as analytically pure sample of compound **7**, **8** or **9** as a yellowish solid.

4.4.1. Compound **7a**

Yellowish solid (80%), mp 164–166 °C. IR (KBr) $\nu_{\rm max}$ 3010, 1691, 1639 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.91 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.7 Hz, $J_{4{\rm aH},7{\rm aH}}$ =3.5 Hz, 4a-H), 5.17 (dd, 1H, $J_{7{\rm aH},7{\rm H}}$ =9.1 Hz, $J_{4{\rm aH},7{\rm aH}}$ =3.5 Hz, 7a-H), 7.56 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.7 Hz, 4-H), 7.64 (d, 1H, $J_{7{\rm aH},7{\rm H}}$ =9.1 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 65.5, 72.3, 159.2, 161.5, 173.4. MS (FAB) m/z 141 (MH $^+$). Anal. Calcd for C₅H₄N₂O₃: C, 42.87; H, 2.88; N, 20.00%. Found: C, 43.18; H, 2.53; N, 19.89%.

4.4.2. Compound 7b

Yellowish solid (83%), mp 159–161 °C. IR (KBr) $\nu_{\rm max}$ 3008, 1632, 1052 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ: 4.07 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.7 Hz, $J_{4{\rm aH},7{\rm aH}}$ =3.9 Hz, 4a-H), 5.13 (dd, 1H, $J_{7{\rm aH},7{\rm H}}$ =9.1 Hz, $J_{4{\rm aH},4{\rm H}}$ =8.7 Hz, 4-H), 7.67 (d, 1H, $J_{7{\rm aH},7{\rm H}}$ =9.1 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ: 65.2, 71.9, 158.7, 161.2, 193.2. MS (FAB) m/z 157 (MH⁺). Anal. Calcd for C₅H₄N₂O₂S: C, 38.46; H, 2.58; N, 17.94%. Found: C, 38.69; H, 2.69; N, 17.76%.

4.4.3. Compound 8a

Yellowish solid (91%), mp 152–154 °C. IR (KBr) ν_{max} 3012, 1696, 1634, 1605, 1581, 1455 cm⁻¹. ¹H NMR

(DMSO- d_6 /TMS) δ : 4.23 (dd, 1H, $J_{4aH,4H}$ =8.2 Hz, $J_{4aH,7aH}$ =3.7 Hz, 4a-H), 5.71 (dd, 1H, $J_{7aH,7H}$ =7.6 Hz, $J_{4aH,7aH}$ =3.7 Hz, 7a-H), 7.12—7.57 (m, 5H_{arom}), 7.56 (d, 1H, $J_{7aH,7H}$ =7.6 Hz, 7-H), 7.69 (d, 1H, $J_{4aH,4H}$ =8.2 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 56.2, 78.3, 121.2, 125.7, 127.7, 130.2, 156.2, 161.3, 172.5. MS (FAB) m/z 216 (MH⁺). Anal. Calcd for C₁₁H₉N₃O₂: C, 61.39; H, 4.22; N, 19.53%. Found: C, 61.03; H, 4.43; N, 19.37%.

4.4.4. Compound 8b

Yellowish solid (93%), mp 168–171 °C. IR (KBr) $\nu_{\rm max}$ 3009, 1631, 1601, 1579, 1449, 1321, 1312, 1057 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 4.19 (dd, 1H, $J_{4aH,4H}$ =8.2 Hz, $J_{4aH,7aH}$ =3.3 Hz, 4a-H), 5.75 (dd, 1H, $J_{7aH,7H}$ =7.6 Hz, $J_{4aH,7aH}$ =3.3 Hz, 7a-H), 7.18–7.61 (m, 5H_{arom}), 7.59 (d, 1H, $J_{7aH,7H}$ =7.6 Hz, 7-H), 7.72 (d, 1H, $J_{4aH,4H}$ =8.2 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 55.9, 81.2, 122.5, 125.9, 127.5, 130.5, 156.5, 161.2, 192.7. MS (FAB) m/z 232 (MH⁺). Anal. Calcd for C₁₁H₉N₃OS: C, 57.13; H, 3.92; N, 18.17%. Found: C, 57.38; H, 3.77; N, 17.95%.

4.4.5. Compound 9a

Yellowish solid (85%), mp 185–187 °C. IR (KBr) $\nu_{\rm max}$ 2998, 1692, 1635 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 1.67 (s, 3H, Me), 3.12 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.9 Hz, 4a-H), 4.57 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =7.9 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.9 Hz, 8a-H), 7.53 (d, 1H, $J_{8{\rm aH},8{\rm H}}$ =7.9 Hz, 8-H), 7.61 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 51.3, 75.2, 159.2, 161.5, 162.7, 163.8, 173.5. MS (FAB) m/z 166 (MH⁺). Anal. Calcd for C₇H₇N₃O₂: C, 50.91; H, 4.27; N, 25.44%. Found: C, 50.67; H, 4.49; N, 25.32%.

4.4.6. Compound 9b

Yellowish solid (82%), mp 159–161 °C. IR (KBr) $\nu_{\rm max}$ 3005, 1631, 1055 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ: 1.72 (s, 3H, Me), 3.15 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.6 Hz, 4a-H), 4.63 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =7.9 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.6 Hz, 8a-H), 7.49 (d, 1H, $J_{8{\rm aH},8{\rm H}}$ =7.9 Hz, 8-H), 7.60 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ: 51.5, 74.8, 157.9, 160.8, 162.5, 163.2, 192.3. MS (FAB) m/z 182 (MH⁺). Anal. Calcd for C₇H₇N₃OS: C, 46.40; H, 3.89; N, 23.19%. Found: C, 46.27; H, 3.95; N, 23.55%.

4.5. 1,2-Oxazino- and pyrazino-1,3-oxazin-2-ones(thiones) **10** and **11**: general procedure

These were prepared by following the similar procedure as described above for 7-9, except that in this case 6 (1 mmol) was used in place of 5 to yield 10 and 11. To obtain analytically pure sample of compounds 10 and 11, the same procedure was adopted as described for 7-9.

4.5.1. Compound 10a

Yellowish solid (81%), mp 173–175 °C. IR (KBr) $\nu_{\rm max}$ 3393, 3008, 1694, 1638 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.85 (dd, 1H, $J_{\rm 8aH,8H}$ =9.3 Hz, $J_{\rm 7H,8H}$ =6.8 Hz, 8-H), 4.03 (dd, 1H, $J_{\rm 4aH,4H}$ =8.9 Hz, $J_{\rm 4aH,8aH}$ =3.3 Hz, 4a-H), 4.78 (dd,

1H, $J_{8aH,8H}$ =9.3 Hz, $J_{4aH,8aH}$ =3.3 Hz, 8a-H), 5.01 (br s, 1H, OH, exchangeable with D₂O), 7.47 (d, 1H, $J_{4aH,4H}$ =8.9 Hz, 4-H), 7.55 (d, 1H, $J_{7H,8H}$ =6.8 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 55.9, 70.9, 81.5, 159.5, 161.5, 173.4. MS (FAB) m/z 171 (MH⁺). Anal. Calcd for $C_6H_6N_2O_4$: C, 42.36; H, 3.55; N, 16.47%. Found: C, 42.64; H, 3.38; N, 16.11%.

4.5.2. Compound 10b

Yellowish solid (88%), mp 181–183 °C. IR (KBr) $\nu_{\rm max}$ 3395, 3006, 1639, 1051 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.87 (dd, 1H, $J_{\rm 8aH,8H}$ =9.2 Hz, $J_{\rm 7H,8H}$ =6.8 Hz, 8-H), 3.99 (dd, 1H, $J_{\rm 4aH,4H}$ =8.9 Hz, $J_{\rm 4aH,8aH}$ =3.3 Hz, 4a-H), 4.81 (dd, 1H, $J_{\rm 8aH,8H}$ =9.2 Hz, $J_{\rm 4aH,8aH}$ =3.3 Hz, 8a-H), 4.99 (br s, 1H, OH, exchangeable with D₂O), 7.44 (d, 1H, $J_{\rm 4aH,4H}$ =8.9 Hz, 4-H), 7.53 (d, 1H, $J_{\rm 7H,8H}$ =6.8 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 56.2, 71.2, 80.9, 160.2, 161.7, 193.4. MS (FAB) m/z 187 (MH⁺). Anal. Calcd for C₆H₆N₂O₃S: C, 38.70; H, 3.25; N, 15.05%. Found: C, 38.51; H, 3.36; N, 15.26%.

4.5.3. Compound 11a

Yellowish solid (92%), mp 133–135 °C. IR (KBr) $\nu_{\rm max}$ 3392, 3003, 1692, 1635 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.81 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.7 Hz, 4a-H), 3.92 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =9.3 Hz, $J_{7{\rm H},8{\rm H}}$ =6.5 Hz, 8-H), 4.81 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =9.3 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.7 Hz, 8a-H), 4.95 (br s, 1H, OH, exchangeable with D₂O), 7.05–7.61 (m, 5H_{arom}), 7.45 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, 4-H), 7.55 (d, 1H, $J_{7{\rm H},8{\rm H}}$ =6.5 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 62.3, 70.7, 81.9, 123.4, 127.9, 129.7, 130.6, 160.2, 161.1, 172.9. MS (FAB) m/z 246 (MH⁺). Anal. Calcd for C₁₂H₁₁N₃O₃: C, 58.77; H, 4.52; N, 17.13%. Found: C, 58.49; H, 4.37; N, 17.29%.

4.5.4. Compound 11b

Yellowish solid (91%), mp 143–145 °C. IR (KBr) $\nu_{\rm max}$ 3390, 3007, 1631, 1057 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.80 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.3 Hz, 4a-H), 3.91 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =9.1 Hz, $J_{7{\rm H},8{\rm H}}$ =6.5 Hz, 8-H), 4.83 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =1.3 Hz, $J_{4{\rm aH},8{\rm aH}}$ =3.3 Hz, 8a-H), 4.98 (br s, 1H, OH, exchangeable with D₂O), 7.09–7.58 (m, 5H_{arom}), 7.48 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, 4-H), 7.56 (d, 1H, $J_{7{\rm H},8{\rm H}}$ =6.5 Hz, 7-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 62.7, 71.5, 82.7, 122.5, 123.7, 127.8, 130.1, 159.8, 161.5, 192.8. MS (FAB) m/z 262 (MH⁺). Anal. Calcd for C₁₂H₁₁N₃O₂S: C, 55.16; H, 4.24; N, 16.08%. Found: C, 55.31; H, 4.13; N, 16.37%.

4.6. Furo- and pyrano-1,3-oxazin-2-ones(thiones) 12 and 13: general procedure

An intimate solvent-free mixture of 1,3-oxazin-2-ones-(thiones) (2 mmol) **3** and montmorillonite K-10 clay (0.20 g) was taken in a 20 mL vial and subjected to MW irradiation at 95 $^{\circ}$ C for 5–8 min to get the crude product, which was extracted with ethyl acetate (3×20 mL). The extract was filtered, the filtrate was evaporated under reduced pressure and the residue thus obtained was recrystallized from ethanol to afford analytically pure sample of **12** or **13**.

4.6.1. Compound 12a

Yellowish solid (85%), mp 113–114 °C. IR (KBr) $\nu_{\rm max}$ 3392, 3015, 1698, 1633 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.56 (dd, 1H, $J_{\rm 6Ha,Hb}$ =11.8 Hz, $J_{\rm 6Ha,7H}$ =4.4 Hz, 6-Ha), 3.81 (dd, 1H, $J_{\rm 6Ha,Hb}$ =11.8 Hz, $J_{\rm 6Hb,7H}$ =2.6 Hz, 6-Hb), 3.94 (ddd, 1H, $J_{\rm 7H,7Ha}$ =8.8 Hz, $J_{\rm 6Ha,7H}$ =4.4 Hz, $J_{\rm 6Hb,7H}$ =2.6 Hz, 7-H), 4.19 (dd, 1H, $J_{\rm 4aH,4H}$ =8.1 Hz, $J_{\rm 4aH,7aH}$ =4.2 Hz, 4a-H), 4.92 (dd, 1H, $J_{\rm 7H,7Ha}$ =8.8 Hz, $J_{\rm 4aH,7aH}$ =4.2 Hz, 7a-H), 5.02 (br s, 1H, OH, exchangeable with D₂O), 7.45 (d, 1H, $J_{\rm 4aH,4H}$ =8.1 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 56.5, 71.3, 81.6, 82.7, 162.6, 172.8. MS (FAB) m/z 158 (MH⁺). Anal. Calcd for C₆H₇NO₄: C, 45.86; H, 4.49; N, 8.91%. Found: C, 45.95; H, 4.57; N, 8.73%.

4.6.2. Compound 12b

Yellowish solid (83%), mp 139–141 °C. IR (KBr) $\nu_{\rm max}$ 3395, 3009, 1635, 1053 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ: 3.55 (dd, 1H, $J_{\rm 6Ha,Hb}$ =12.1 Hz, $J_{\rm 6Ha,7H}$ =4.1 Hz, 6-Ha), 3.76 (dd, 1H, $J_{\rm 6Ha,Hb}$ =12.1 Hz, $J_{\rm 6Hb,7H}$ =2.6 Hz, 6-Hb), 3.88 (ddd, 1H, $J_{\rm 7H,7Ha}$ =8.9 Hz, $J_{\rm 6Ha,7H}$ =4.1 Hz, $J_{\rm 6Hb,7H}$ =2.6 Hz, 7-H), 4.21 (dd, 1H, $J_{\rm 4aH,4H}$ =8.2 Hz, $J_{\rm 4aH,7aH}$ =4.2 Hz, 4a-H), 4.89 (dd, 1H, $J_{\rm 7H,7Ha}$ =8.9 Hz, $J_{\rm 4aH,7aH}$ =4.2 Hz, 7a-H), 4.97 (br s, 1H, OH, exchangeable with D₂O), 7.48 (d, 1H, $J_{\rm 4aH,4H}$ =8.2 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ: 58.2, 70.9, 79.8, 81.8, 163.2, 192.5. MS (FAB) m/z 174 (MH⁺). Anal. Calcd for C₆H₇NO₃S: C, 41.61; H, 4.07; N, 8.09%. Found: C, 41.39; H, 4.21; N, 7.88%.

4.6.3. Compound 13a

4.6.4. Compound 13b

Yellowish solid (87%), mp 173–175 °C. IR (KBr) $\nu_{\rm max}$ 3393, 3382, 3009, 1633, 1058 cm⁻¹. ¹H NMR (DMSO- d_6/TMS) δ : 3.43 (ddd, 1H, $J_{6{\rm Ha,7H}}$ =9.3 Hz, $J_{7{\rm H,8H}}$ =9.0 Hz, $J_{6{\rm Hb,7H}}$ =3.8 Hz, 7-H), 3.61 (dd, 1H, $J_{6{\rm Ha,Hb}}$ =12.4 Hz, $J_{6{\rm Ha,7H}}$ =9.3 Hz, 6-Ha), 3.89 (dd, 1H, $J_{6{\rm Ha,Hb}}$ =12.4 Hz, $J_{6{\rm Hb,7H}}$ =3.8 Hz, 6-Hb), 4.06 (dd, 1H, $J_{7{\rm H,8H}}$ =9.0 Hz, $J_{8{\rm H,8Ha}}$ =8.8 Hz, 8-H), 4.14 (dd, 1H, $J_{4{\rm aH,4H}}$ =8.1 Hz, $J_{4{\rm aH,8aH}}$ =3.2 Hz, 4a-H), 4.24 (dd, 1H, $J_{8{\rm H,8aH}}$ =8.8 Hz, $J_{4{\rm aH,8aH}}$ =3.2 Hz, 8a-H), 4.93–5.19 (br s, 2H, 2×OH, exchangeable with D₂O), 7.51 (d, 1H, $J_{4{\rm aH,4H}}$ =8.2 Hz, 4-H). ¹³C NMR (DMSO- d_6/TMS) δ : 65.2, 71.3, 76.5, 81.4, 83.1, 162.8, 193.2. MS (FAB) m/z 204 (MH⁺). Anal. Calcd for C₇H₉NO₄S: C, 41.37; H, 4.46; N, 6.89%. Found: C, 41.55; H, 4.29; N, 6.63%.

4.7. 4-Amino oxazine-2,6-diones(6-one-2-thiones) 14: general procedure

Thoroughly mixed phenylurea (0.272 g, 2 mmol), aldehyde 5 (0.286 g for 5a, 2 mmol), ammonium acetate (0.154 g, 2 mmol) and montmorillonite K-10 clay (0.20 g) were taken in a 20 mL vial subjected to microwave irradiation at 90 °C for 9–10 min. After completion of the reaction as indicated by TLC (hexane/AcOEt, 8:2, v/v), the product was extracted with dichloromethane (3×20 mL), the extract was filtered and the filtrate was evaporated under reduced pressure to leave the crude product, which was recrystallized from ethanol to obtain an analytically pure sample of 14 as yellowish needles.

4.7.1. Compound 14a

Yellowish solid (89%), mp 181–182 °C. IR (KBr) $\nu_{\rm max}$ 3342, 3007, 1691, 1638 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 2.98–3.12 (br s, 2H, NH, exchangeable with D₂O), 4.32 (dd, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, $J_{4{\rm aH},8{\rm aH}}$ =2.9 Hz, 4a-H), 4.97 (dd, 1H, $J_{8{\rm aH},8{\rm H}}$ =7.3 Hz, $J_{4{\rm aH},8{\rm aH}}$ =2.9 Hz, 8a-H), 5.78 (m, 1H, 8-H), 7.03–7.51 (m, 5H_{arom}), 7.58 (d, 1H, $J_{4{\rm aH},4{\rm H}}$ =8.5 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 55.8, 76.5, 81.3, 125.1, 128.2, 129.4, 130.7, 161.5, 172.1, 173.4. MS (FAB) m/z 262 (MH⁺). Anal. Calcd for C₁₂H₁₁N₃O₄: C, 55.17; H, 4.24; N, 16.09%. Found: C, 55.39; H, 4.11; N, 16.31%.

4.7.2. Compound 14b

Yellowish solid (93%), mp 168–171 °C. IR (KBr) $\nu_{\rm max}$ 3347, 3011, 1699, 1631, 1057 cm⁻¹. ¹H NMR (DMSO- d_6/I TMS) δ : 2.94–3.10 (br s, 2H, NH, exchangeable with D₂O), 4.27 (dd, 1H, $J_{\rm 4aH,4H}$ =8.0 Hz, $J_{\rm 4aH,8aH}$ =2.9 Hz, 4a-H), 5.01 (dd, 1H, $J_{\rm 8aH,8H}$ =7.3 Hz, $J_{\rm 4aH,8aH}$ =2.9 Hz, 8a-H), 5.83 (m, 1H, 8-H), 7.12–7.65 (m, 5H_{arom}), 7.53 (d, 1H, $J_{\rm 4aH,4H}$ =8.0 Hz, 4-H). ¹³C NMR (DMSO- d_6/I TMS) δ : 55.2, 75.9, 82.5, 126.2, 127.9, 128.8, 130.1, 162.7, 172.7, 193.2. MS (FAB) m/z 278 (MH⁺). Anal. Calcd for C₁₂H₁₁N₃O₃S: C, 51.98; H, 4.00; N, 15.15%. Found: C, 51.67; H, 4.29; N, 15.21%.

4.8. Oxazine-2,6-diones(6-one-2-thiones) 16

Thoroughly mixed aldehyde **5** (0.286 g for **5a**, 2 mmol), semicarbazide hydrochloride (0.223 g, 2 mmol), sodium acetate (0.164 g, 2 mmol) and montmorillonite K-10 clay (0.10 g) were taken in a 20 mL vial and subjected to microwave irradiation at 90 °C for 8-11 min to afford crude product, which was extracted with dichloromethane (3×20 mL). The extract was filtered and the filtrate was evaporated under reduced pressure to leave the product, which was recrystallized from ethanol to obtain analytically pure sample of **16**.

4.8.1. Compound **16a**

Yellowish solid (91%), mp 163–165 °C. IR (KBr) $\nu_{\rm max}$ 2995, 1695, 1638 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 4.32 (d, 2H, $J_{4,4aH}(J_{8,8aH})$ =8.2 Hz, 4a-H, 8a-H), 7.56 (d, 2H, $J_{4,4aH}(J_{8,8aH})$ =8.2 Hz, 4-H, 8-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 71.5, 162.3, 172.5. MS (FAB) m/z 169 (MH⁺).

Anal. Calcd for $C_6H_4N_2O_4$: C, 42.87; H, 2.40; N, 16.66%. Found: C, 42.61; H, 2.61; N, 16.49%.

4.8.2. Compound 16b

Yellowish solid (90%), mp 175–177 °C. IR (KBr) $\nu_{\rm max}$ 3002, 1693, 1633, 1053 cm⁻¹. ¹H NMR (DMSO- d_6 /TMS) δ : 3.98 (dd, 1H, $J_{\rm 4H,4aH}$ =7.9 Hz, $J_{\rm 4aH,8aH}$ =5.5 Hz, 4a-H), 4.05 (d, 1H, $J_{\rm 8H,8aH}$ =6.3 Hz, 8-H), 4.19 (dd, 1H, $J_{\rm 8H,8aH}$ =6.3 Hz, $J_{\rm 4aH,8aH}$ =3.1 Hz, 8a-H), 7.51 (d, 1H, $J_{\rm 4,4aH}$ =7.9 Hz, 4-H). ¹³C NMR (DMSO- d_6 /TMS) δ : 65.5, 71.9, 161.9, 172.5, 193.1. MS (FAB) m/z 185 (MH⁺). Anal. Calcd for $C_6H_4N_2O_3S$: C, 39.13; H, 2.19; N, 15.21%. Found: C, 39.38; H, 2.12; N, 15.43%.

Acknowledgements

We sincerely thank the CSIR, New Delhi, for financial support. We are also thankful to SAIF, Punjab University, Chandigarh, for providing microanalyses and spectra.

References and notes

- Fitzmaurice, R. J.; Etheridge, Z. C.; Jumel, E.; Woolfson, D. N.; Caddick, S. Chem. Commun. 2006, 4814

 –4816.
- 2. Tan, D. S. Nature Chem. Biol. 2005, 1, 74-84.
- 3. Burke, M. D.; Schreiber, S. L. Angew. Chem., Int. Ed. 2004, 43, 46-58.
- 4. Spring, D. R. Org. Biomol. Chem. 2003, 1, 3867-3870.
- 5. Schreiber, S. L. Science 2000, 287, 1964–1969.
- Bunin, B. A.; Plunkett, M.; Ellman, J. A. Proc. Natl. Acad. Sci. U.S.A. 1994, 81, 4708–4712.
- Corey, E. J.; Cheng, X.-M. The Logic of Chemical Synthesis; John Wiley and Sons: New York, NY, 1989; 423.

- Kobayashi, M.; Kitazawa, M.; Sotio, T.; Yamamoto, R.; Harada, H. Yakugaku Zasshi 1984, 104, 659-679; Chem. Abstr. 1985, 102, 6344m.
- Testa, E.; Fontanella, L.; Cristiani, G.; Gallo, G. J. Org. Chem. 1959, 24, 1928–1936
- (a) Raynaud, G.; Sergant, M.; Douzon, C.; Fauran, C. U.S. 3,821,215, 1974; Chem. Abstr. 1975, 82, 49951r; (b) Vrouenraets, S. M.; Wit, W. F.; van Tongeren, J.; Lange, J. M. Expert Opin. Pharmacother. 2007, 8 851–871
- Abbas, T. R.; Cadogan, J. I. G.; Doyle, A. A.; Gosney, I.; Hodgson, P. K. G.; Howells, G. E.; Hulme, A. N.; Parsons, S.; Sadler, I. H. *Tetrahedron Lett.* 1997, 38, 4917–4920 and references cited therein.
- Klash, A.; Koristek, K.; Polis, J.; Kosmrlj, J. Tetrahedron 2000, 56, 1551–1560.
- Mindl, J.; Hrabik, O.; Sterba, V.; Kavalek, J. Collect. Czech. Chem. Commun. 2000, 65, 1262-1272.
- 14. Waxman, L.; Darke, P. L. Antiviral Chem. Chemother. 2000, 11, 1-6.
- 15. Girgis, A. S. Pharmazie 2000, 426-430.
- Patel, M.; Ko, S. S.; Mc Hugh, R. J., Jr.; Markwalder, J. A.; Srivastava,
 A. S.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S.; Trainor,
 G. L.; Seitz, S. P. Bioorg. Med. Chem. Lett. 1999, 9, 2805–2810.
- Patel, M.; Mc Hugh, R. J., Jr.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S.; Trainor, G. L.; Koo, S. S. *Bioorg. Med. Chem. Lett.* 1999, 9 3221–3226
- 18. Thomas, K. Tetrahedron 2005, 61, 3091-3096.
- Dijkstra, H. P.; Gaulon, C.; Niculescu-Duvaz, D.; Springer, C. J. Synlett 2006, 1519–1522.
- Yadav, L. D. S.; Singh, S.; Singh, A. Tetrahedron Lett. 2002, 43, 8551

 8553.
- 21. Yadav, L. D. S.; Yadav, B. S.; Dubey, S. Tetrahedron 2004, 60, 131-136.
- 22. Yadav, L. D. S.; Kapoor, R. J. Org. Chem. 2004, 69, 8118-8120.
- 23. Yadav, L. D. S.; Kapoor, R. Synlett 2005, 3055-3058.
- Yadav, L. D. S.; Yadav, B. S.; Rai, V. K. Tetrahedron Lett. 2004, 45, 5351–5353.
- 25. Yadav, L. D. S.; Rai, V. K. Tetrahedron Lett. 2006, 47, 395-397.
- 26. Yadav, L. D. S.; Rai, V. K. Synlett 2007, 1227-1230.
- Yadav, L. D. S.; Awasthi, C.; Rai, V. K.; Rai, A. Tetrahedron Lett. 2007, 48, 4899–4902.
- 28. Yadav, L. D. S.; Rai, A.; Rai, V. K.; Awasthi, C. Synlett 2007, 1905-1908.